Ipca Laboratories Limited has released its Annual Report for the financial year ended 31st March, 2026, presenting a comprehensive picture of strong revenue growth, a sharp improvement in profitability, and significant progress on its manufacturing expansion agenda. The 76th Annual General Meeting of the company is scheduled for Thursday, 13th August, 2026, through Video Conferencing/Other Audio Visual Means.

Financial Performance: Standalone and Consolidated

The company delivered a strong financial performance in FY2025-26. On a standalone basis, total income grew 10.11% to ₹7,431.39 Crores from ₹6,749.21 Crores in the previous year. Standalone net profit after tax surged 74.03% to ₹1,132.52 Crores from ₹650.76 Crores. On a consolidated basis, total income increased 8.73% to ₹9,820.78 Crores from ₹9,032.39 Crores, with consolidated net profit attributable to owners of the company at ₹1,141.12 Crores versus ₹737.68 Crores in the prior year.

The following table summarises the key standalone and consolidated financial results:

Standalone earnings per share (after exceptional items) improved to ₹44.64 from ₹25.65 in the previous year. The standalone net worth stood at ₹7,979.35 Crores as at 31st March, 2026, compared to ₹6,891.62 Crores in the previous year.

Sales Breakdown and Key Financial Ratios

Standalone total sales grew 10% to ₹7,295.56 Crores in FY2025-26 from ₹6,639.52 Crores in FY2024-25. Domestic formulations business recorded a 10% growth to ₹3,817.24 Crores, while international business grew 11% to ₹3,129.43 Crores. The APIs and Intermediates segment recorded sales of ₹1,395.74 Crores, up from ₹1,265.84 Crores in the previous year, with nearly 75% of this business from exports.

Key standalone financial ratios reflected the improved business performance:

International Business and Continent-wise Exports

The company's products are exported to over 100 countries. Continent-wise, Europe contributed ₹884.59 Crores (growth of 10%), Africa ₹594.48 Crores (growth of 9%), Americas ₹665.33 Crores (growth of 24%), Asia ₹398.17 Crores (growth of 2%), CIS ₹269.18 Crores (growth of 9%), and Australasia ₹317.68 Crores (growth of 12%). The company has 60 registered generic formulation dossiers in Europe and 76 registered dossiers in Australasia. In the US market, 32 out of 46 filed ANDA applications have been granted to date, and 50 DMFs are currently filed with the US FDA.

Manufacturing Facilities and Capacity Expansion

Several significant manufacturing developments were reported during the year:

• A new greenfield Drug Intermediates/API manufacturing facility at Village Hingni, District Wardha, Maharashtra, with a capital outlay of ₹182 crores, commenced commercial production in February 2026.
• A new greenfield formulations manufacturing unit at Dewas, Madhya Pradesh, with a capital outlay of about ₹275 crores, is expected to commence trial production in the current financial year.
• A new greenfield Monoclonal Antibodies (mAbs) manufacturing facility at Pithampur, Madhya Pradesh, with a capital outlay of about ₹250 crores, is expected to commence production of batches for clinical studies and regulatory approvals in the current financial year.
• The company's step-down subsidiary Pisgah Laboratories Inc., USA, is setting up a new greenfield liquid injectables and oral liquids manufacturing facility at Pisgah Forest, NC USA, at a capital outlay of about US$22 millions, expected to commence trial production in the current financial year.

As part of its operational strategy, the company sold its formulations manufacturing facility at Tarapur, Maharashtra, and its drug intermediates and API manufacturing facility at Ankleshwar, Gujarat, both on a slump sale basis during the year.

Dividend, Credit Ratings, and R&D

The Board has recommended a dividend of ₹6/- per equity share of Re. 1 each (600%) for FY2025-26, totalling ₹152.22 Crores if approved at the AGM. The record date for the dividend has been fixed as Friday, 7th August, 2026.

India Ratings & Research (A Fitch Group Company) has assigned/affirmed the following ratings:

R&D expenditure for FY2025-26 was ₹246.09 Crores, representing 3.37% of turnover, compared to ₹207.08 Crores (3.12% of turnover) in the previous year. The company has R&D centres at Mumbai, Ratlam, Athal (Silvassa), and Ranu (Vadodara), all recognised by the Department of Scientific & Industrial Research.

Corporate Governance and AGM

The 76th AGM is scheduled for 13th August, 2026, through VC/OAVM. Key agenda items include adoption of audited financial statements for FY2025-26, declaration of dividend, re-appointment of Mr. Ajit Kumar Jain and Mr. Pranay Godha as directors retiring by rotation, and re-appointment of Mr. Prashant Godha as Executive Director for a further period of five years with effect from 16th August, 2026. The company has 18,667 permanent employees (including 1,035 overseas employees) as on 31st March, 2026. The paid-up share capital stands at ₹25.37 Crores, comprising 25,37,04,218 equity shares of ₹1/- each. Promoter shareholding stands at 44.72% as at 31st March, 2026.

Ipca Laboratories Limited will conduct its 76th Annual General Meeting (AGM) on Thursday, August 13, 2026, at 3:30 p.m. through Video Conferencing and Other Audio Visual Means (VC/OAVM). The meeting is being held in compliance with the Companies Act, 2013, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Members attending through VC/OAVM will be counted for the purpose of quorum under Section 103 of the Act.

The Notice of the AGM and the Financial Statements for the financial year 2025-26, along with the Annual Report, will be sent only via email to members whose email addresses are registered with the company, its Registrars and Share Transfer Agents (RTA), or Depository Participants (DP). These documents are also available on the company's website at www.ipca.com , the websites of BSE Limited and the National Stock Exchange of India Ltd., and National Securities Depository Services Ltd. (NSDL) at www.evoting.nsdl.com .

The company is providing members with the facility to vote on agenda items through remote e-voting and e-voting during the AGM using the services of NSDL. Detailed procedures for remote e-voting and e-voting at the AGM have been provided in the Notice of AGM. Members holding shares in physical mode must send an email to the company or the RTA with specific details, including a self-attested copy of the PAN Card and address proof, to register or update their email address and bank details. Those holding shares in demat mode must contact their DP to register these details.

In a separate filing, Ipca Laboratories Limited informed the exchanges about the loss of a share certificate. The certificate, registered in the name of Sushil Gattani jointly with Sumita Gattani, bears Folio No. 0029462 and Certificate No. 314. The certificate represents 2,000 shares of face value ₹1 each, with distinctive numbers ranging from 605001 to 607000. The public has been cautioned against purchasing or dealing with the aforementioned share certificates.

Any person with a claim regarding the lost share certificate must lodge it with the company or its Registrar and Transfer Agents, MUFG Intime India Private Limited, within 15 days of the publication of this notice. Following this period, the company will proceed to issue a duplicate share certificate, and no further claims will be entertained.